Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention.

Background: The aim of this study was to assess the reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention.

Methods: The study design was a methodological systematic review of randomized controlled trials. The data sources were MEDLINE and the Cochrane Central Register of Controlled Trials.

Quality of reporting internal and external validity data from randomized controlled trials evaluating stents for percutaneous coronary intervention.

Background: Stents are commonly used to treat patients with coronary artery disease. However, the quality of reporting internal and external validity data in published reports of randomised controlled trials (RCTs) of stents has never been assessed.The objective of our study was to evaluate the quality of reporting internal and external validity data in published reports of RCTs assessing the stents for percutaneous coronary interventions.

Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease.

Background: Reports of clinical trials usually emphasize benefits and give less attention to harms.

Purpose: To compare the reporting of harm in trials of pharmacologic and nonpharmacologic treatment.

Data Sources: MEDLINE and the Cochrane Central Register of Controlled Trials.

Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France.

Unlabelled: When the anti-TNFalpha drugs first came onto the market, their high price was the subject of much debate. Moreover, we must add the costs associated with their administration to the purchase price. Variations in medical practices may be the source of substantial variations in these costs.